Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.
The closing price of Tonix Pharmaceuticals Holding Corp (NASDAQ: TNXP) was $13.63 for the day, up 1.19% from the previous closing price of $13.47. In other words, the price has increased by $1.19 from its previous closing price. On the day, 0.77 million shares were traded.
Ratios:
Our analysis of TNXP’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 2.78 and its Current Ratio is at 3.33. In the meantime, Its Debt-to-Equity ratio is 0.12 whereas as Long-Term Debt/Eq ratio is at 0.08.
On April 18, 2019, ROTH Capital Upgraded its rating to Buy which previously was Neutral but kept the price unchanged to $4.
ROTH Capital Upgraded its Neutral to Buy on August 18, 2017, while the target price for the stock was maintained at $6.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 6.75 while its Price-to-Book (P/B) ratio in mrq is 28.58.
Stock Price History:
Over the past 52 weeks, TNXP has reached a high of $1216.00, while it has fallen to a 52-week low of $6.76. The 50-Day Moving Average of the stock is -36.05%, while the 200-Day Moving Average is calculated to be -78.47%.
Shares Statistics:
A total of 155.63M shares are outstanding, with a floating share count of 5.59M. Insiders hold about 0.00% of the company’s shares, while institutions hold 2.86% stake in the company.
Earnings Estimates
The consensus estimate for the next quarter is -$640, with high estimates of -$640 and low estimates of -$640.
Analysts are recommending an EPS of between $0 and $0 for the fiscal current year, implying an average EPS of $0. EPS for the following year is -$2784, with 1 analysts recommending between -$2784 and -$2784.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 2 analysts. It ranges from a high estimate of $4.1M to a low estimate of $2.6M. As of the current estimate, Tonix Pharmaceuticals Holding Corp’s year-ago sales were $3.78MFor the next quarter, 2 analysts are estimating revenue of $4.2M. There is a high estimate of $4.2M for the next quarter, whereas the lowest estimate is $4.2M.
A total of 2 analysts have provided revenue estimates for TNXP’s current fiscal year. The highest revenue estimate was $15.8M, while the lowest revenue estimate was $10.1M, resulting in an average revenue estimate of $12.95M. In the same quarter a year ago, actual revenue was $7.77MBased on 2 analysts’ estimates, the company’s revenue will be $17.25M in the next fiscal year. The high estimate is $17.3M and the low estimate is $17.2M.
